Filing Flows › Health Care › PTC Therapeutics (PTCT)
PTC Therapeutics (PTCT) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Oct 29, 2026 · PTC Therapeutics (PTCT) Q3 2026 earnings results →
Q3 2026 Revenue up 70% year over year to $358M · 14¢ of every $1 of revenue lost · operating margin 7.0%
PTC Therapeutics made $358M in Q3 2026 (+70% Y/Y): Net product revenue $276M, Royalty revenue $81.7M, Collaboration and license revenue $229K. Operating margin 7.0%, net loss $51.7M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Oct 29, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $357.8M in Q3 2026, up 70% year over year and down 1% from the previous quarter. Sephience was the largest line at 51% of revenue. Sephience added $162.3M year over year (up 830%), 111% of the total change. Collaboration and license revenue declined 98%.
Operating profit was $25.1M, a 7.0% margin (up 5.6 points year over year). Of the extra revenue versus Q3 2025, 15% reached operating profit, above the 1% margin then. Total costs grew 60% against revenue growth of 70%. The fastest-growing cost line was Other operating costs (+519%). The quarter ended with a net loss of $51.7M, after a profit of $83.5M the previous quarter. Net interest and other expense of $66.2M was the main reason.
Operating cash flow was −$25.3M. Non-cash charges added back $16.8M of depreciation and amortization and $23.8M of share-based compensation. Working capital and other items used $14.3M. Capital expenditures of $2.7M exceeded it, leaving free cash flow of −$28.0M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Oct 29, 2026 | $358M | +70% | 7.0% | −$51.7M | −$25.3M |
| Q2 2026 | 10-Q | Jul 30, 2026 | $361M | +102% | 41.3% | $83.5M | $129M |
| Q1 2026 | 10-Q | May 7, 2026 | $273M | -77% | 16.5% | −$2.8M | −$59.0M |
| Q4 2025 | 10-K | Feb 19, 2026 | $165M | -23% | -43.3% | −$135M | −$34.3M |
| Q3 2025 | 10-Q | Nov 4, 2025 | $211M | +7% | 1.4% | $15.9M | −$66.3M |
| Q2 2025 | 10-Q | Aug 7, 2025 | $179M | -4% | -19.5% | −$64.8M | −$58.3M |
| Q1 2025 | 10-Q | May 6, 2025 | $1.2B | +460% | 82.5% | $867M | $870M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Buys from
About PTC Therapeutics
We are a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. We are advancing a robust and diversified pipeline of transformative medicines as part of our mission to provide access to best-in-class treatments for patients with unmet medical needs. Our strategy is to leverage our scientific expertise and global commercial infrastructure to optimize value for our patients and other stakeholders. We have a diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism.
In its own words, from its 10-K, filed Feb 19, 2026.
PTC Therapeutics against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +70% against the peers' median +10%. Operating margin: 7.0% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| PTCT PTC Therapeutics | Q3 2026 | $358M | +70% | 7.0% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: PTC Therapeutics 10-Q on SEC EDGAR · CIK 1070081 · Pharmaceutical Preparations
Guidance and outlook
13F: who owns PTCT and who is buying
More on PTCT
- How PTC Therapeutics makes money: revenue by segment
- PTC Therapeutics next earnings date and what analysts expect
- PTC Therapeutics stock forecast, price target and fair value
- Who owns PTC Therapeutics stock: holders, funds and Congress trades
- PTC Therapeutics guidance and outlook
- Is PTC Therapeutics a takeover target? LBO and rumors
- PTC Therapeutics recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results